Bacterin International Holdings Mulls Acquisitions
Mar 18 15
Bacterin International Holdings, Inc. (AMEX:BONE) is seeking acquisition. Dan Goldberger, Chief Executive Officer of Bacterin International Holdings, said in Bacterin International Holdings earnings call, "In addition to our own developments, we are evaluating a number of acquisition opportunities that would leverage our regenerative medicine focus and our rapidly growing distribution capability that calls on orthopedic and neurosurgeons.”
Bacterin International Holdings, Inc. Announces Audited Consolidated Earnings Results for the Fourth Quarter and Year Ended December 31, 2014; Provides Earnings Guidance for Full Year 2015; Reports Impairment of Assets
Mar 17 15
Bacterin International Holdings, Inc. announced audited consolidated earnings results for the fourth quarter and year ended December 31, 2014. For the quarter, the company reported total revenue of $9,081,406 against $8,257,776 a year ago. Loss from operations was $2,490,364 against $3,559,750 a year ago. Net loss from operations before income taxes was $3,302,297 against $4,164,243 a year ago. Net loss was $3,302,297 or $0.49 per basic and diluted share against $4,164,243 or $0.83 per basic and diluted share a year ago. EBITDA was a loss of $1.1 million compared to a loss of $1.6 million for the same period during 2013.
For the year, the company reported total revenue of $35,331,812 against $33,073,414 a year ago. Loss from operations was $6,264,729 against $9,007,579 a year ago. Net loss from operations before income taxes was $10,507,869 against $12,693,125 a year ago. Net loss was $10,507,869 or $1.76 per basic and diluted share against $12,693,125 or $2.80 per basic and diluted share a year ago. Net cash used in operating activities was $7,324,059 against $4,892,306 a year ago. Purchases of property and equipment and intangible assets were $299,978 against $623,045 a year ago. EBITDA was a loss of $3.5 million compared to an EBITDA loss of $5.8 million in the prior year.
Based on the planned growth of the company's hybrid salesforce, combined with new product launches, the company currently anticipates 2015 full-year revenue to be in the range of $40 million to $42 million compared to $35.3 million reported for 2014. The company is forecasting 61% to 63% gross margin for 2015.
For the quarter, the company reported impairment of assets was $912,549 against $728,618 a year ago.
Bacterin International Holdings, Inc. Announces Contract Extension with Novation
Mar 16 15
Bacterin International Holdings, Inc. announced that it has extended its contract with Novation for an additional year. The extension will allow Bacterin to continue to supply Novation members with OsteoSponge, OsteoSelect DBM Putty, and other proprietary Bacterin allografts. Novation develops and manages competitive contracts with more than 700 suppliers. As a biologic supplier, Bacterin is one of only three companies with a contract for demineralized bone matrix technologies and one of four allograft suppliers.
Bacterin International Holdings, Inc. Presents at Canaccord Genuity 10th Annual Musculoskeletal Conference, Mar-24-2015 02:00 PM
Mar 11 15
Bacterin International Holdings, Inc. Presents at Canaccord Genuity 10th Annual Musculoskeletal Conference, Mar-24-2015 02:00 PM. Venue: MGM Grand Hotel, Las Vegas, Nevada, United States. Speakers: Daniel Goldberger, Chief Executive Officer and Director.
Bacterin International Holdings, Inc Announces Distribution Agreement with Spartan Medical
Mar 10 15
Bacterin International Holdings, Inc. announced that it has signed a national distribution agreement with Spartan Medical, Inc. Under the agreement, Spartan Medical will distribute Bacterin's proprietary product portfolio to the medical centers affiliated with the US Department of Defense (DOD) and the US Department of Veteran's Affairs (VA).